Phathom Pharmaceuticals, Inc. (PHAT)
NASDAQ: PHAT · Real-Time Price · USD
8.39
+0.16 (1.94%)
At close: Aug 6, 2026, 4:00 PM EDT
8.43
+0.04 (0.48%)
Pre-market: Aug 7, 2026, 8:07 AM EDT
Phathom Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 11 analysts polled by S&P Global, Phathom Pharmaceuticals stock has a consensus rating of "Strong Buy" and an average price target of $21.9. The average 1-year stock price forecast is 161.03% higher than the current stock price, while the lowest is $13 (+54.95%) and the highest is $29 (+245.65%).
Price Target: $21.9 (+161.03%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Phathom Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 8 | 8 | 7 | 7 | 7 | 8 |
| Buy | 1 | 2 | 2 | 2 | 2 | 2 |
| Hold | 2 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 11 | 11 | 10 | 10 | 10 | 11 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Craig-Hallum | Craig-Hallum | Buy Reiterates $22 → $20 | Buy | Reiterates | $22 → $20 | +138.38% | Jul 31, 2026 |
| Raymond James | Raymond James | Buy Maintains $21 | Buy | Maintains | $21 | +150.30% | Jul 31, 2026 |
| Guggenheim | Guggenheim | Buy Maintains $25 → $22 | Buy | Maintains | $25 → $22 | +162.22% | Jul 31, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $26 | Buy | Reiterates | $26 | +209.89% | Jul 31, 2026 |
| Needham | Needham | Buy Maintains $28 → $22 | Buy | Maintains | $28 → $22 | +162.22% | Jul 30, 2026 |
Financial Forecast
Revenue This Year
316.56M
from 175.11M
Increased by 80.78%
Revenue Next Year
494.34M
from 316.56M
Increased by 56.16%
EPS This Year
-0.00
from -2.06
EPS Next Year
1.14
from -0.00
EPS and Forward PE are based on non-GAAP adjusted numbers.